As the selective reduction of the expression level of SGIP1 resulted in the inhibition of food intake and the reduction of body weight in rat models of obesity and diabetes18, SGIP1 seems to be a potential therapeutic target for obesity- and diabetes-related symptoms. This evidence concerns the gene SGIP1 and obesity disorder.